Efficacy and Safety of Cemdisiran siRNA in Myasthenia Gravis

episode

Neurology Minute not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Could sofa theory help you find your ideal partner? 4 min · 23 Sep 2026 · Do you really know?

Is end-to-end encryption really secure? 4 min · 23 Sep 2026 · Do you really know?

Do tongue scrapers actually help with bad breath? 5 min · 23 Sep 2026 · Do you really know?

Is it cool to have no friends? 26 min · 23 Sep 2026 · Today in Focus

The Songs of John Farnham: A Living Legend | Tony Cochrane (23.09.26) 7 min · 23 Sep 2026 · Whateley

Las 10 de Erazno, el Chokolatazo, Parodias, 1h 29m · 23 Sep 2026 · Erazno y La Chokolata El Podcast

Report any issue

Source

Recorded12 Aug 2026

Publisherneurologyminute.libsyn.com ↗

Handlerec:19727372

Show notes

Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis. Show citation: Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in